And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release.

The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone treatment ... the manufacturer Johnson & Johnson said in a press release. The study found that ...

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals ... Milestone said Friday that the FDA has issued a so-called complete response letter ...

FDA grants Fast Track designation to J&J’s nipocalimab for moderate-to-severe Sjögren’s disease, boosting its regulatory pathway. Phase 2 trial shows over 70% improvement in disease activity ...

Johnson & Johnson (J&J ... In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder (who were ...

The company states: “Johnson & Johnson ... active Crohn’s disease, CD, a chronic inflammatory condition of the gastrointestinal tract. This milestone builds upon the FDA approval of TREMFYA ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is the fourth ...

The FDA has approved Johnson & Johnson’s (J&J) Tremfya (guselkumab) for the treatment of moderately to severely active Crohn disease (CD). The regulatory action makes Tremfya the first and only ...